



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chris DOTT et al

Serial No.: 10/581671

Filed: June 5, 2006

For: BOTULINUM TOXIN TREATMENT  
OF SPASTIC BLADDER

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR §1.56, and in accordance with 37 CFR §§1.97 and 1.98, Applicant(s), through the undersigned attorney, submits this Information Disclosure Statement. The patents, publications or other information submitted herewith are listed on the attached Form PTO-1449 and copies are attached excluding U.S. patents and publications.

The documents listed on the attached Form PTO-1449 were cited in the International Search Report. A copy of the ISR is attached.


Documents AD and AG listed on Form PTO-1449 were also cited in a Great Britain Search Report in a counterpart Great Britain patent application. A copy of the British Search Report is enclosed.

In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits of the above-identified application.


Respectfully submitted,

JACOBSON HOLMAN PLLC

By:

  
\_\_\_\_\_  
John C. Holman  
Registration No. 22,769  
400 Seventh Street, N.W.  
Washington, DC 20004-2218  
(202) 638-6666

Atty. Dkt. No.: P71305US0  
Date: October 13, 2006



**JACOBSON HOLMAN PLLC**  
 400 SEVENTH STREET, N.W.  
 WASHINGTON, D.C. 20004-2201

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: P71305US0 GROUP ART UNIT: \_\_\_\_\_  
 SERIAL NO.: 10/581671 FILING DATE: June 5, 2006  
 APPLICANT(S): DOTT et al TODAY'S DATE: October 13, 2006

\*\*\*\*\*  
**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE If Appropriate
_____	AA <u>5437291</u>	<u>08/01/95</u>	<u>Pasricha et al</u>	<u>128</u>	<u>898</u>	_____
_____	AB <u>6638246</u>	<u>10/28/03</u>	<u>Naimark et al</u>	<u>604</u>	<u>103</u>	_____
_____	AC <u>2002/0099356</u>	<u>07/25/02</u>	<u>Unger et al</u>	<u>604</u>	<u>501</u>	_____
_____	AD <u>2003/0108597</u>	<u>06/12/03</u>	<u>Chancellor et al</u>	<u>424</u>	<u>450</u>	_____
_____	AE <u>2003/0211975</u>	<u>11/13/03</u>	<u>Unger</u>	<u>514</u>	<u>2</u>	_____

\*\*\*\*\*  
**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES) (NO)
_____	AF <u>WO99/03483</u>	<u>01/28/99</u>	<u>WIPO</u>	_____	_____	
_____	AG <u>WO04/010934</u>	<u>02/05/04</u>	<u>WIPO</u>	_____	_____	
_____	AH _____	_____	_____	_____	_____	

\*\*\*\*\*  
**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

_____	AI	<u>Dykstra et al, ARCH PHYS MED REHABIL Vol 71, Jan. 1990, pgs. 24-26, Treatment of Detrusor-Sphincter Dyssynergia with Botulinum..</u>				
_____	AJ	<u>Yokoyama et al, ACTA MED Vol 56, No 6, 2002, pgs. 271-277, Botulinum Toxin Treatment of Urethral and Bladder Dysfunction</u>				
_____	AK	_____				

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)